MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-06-2025
Altimmune Long Term Debt Current 2011-2025 | ALT
Annual Long Term Debt Current Altimmune
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 279 K | 496 K | 452 K | 411 K | 357 K | 259 K | - | - | - | - | 746 K | 1 M | 750 K | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1 M | 259 K | 528 K |
Long Term Debt Current of other stocks in the Biotechnology industry
| Issuer | Long Term Debt Current | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
3.63 M | - | 2.43 % | $ 254 M |  Germany |
 |
Arbutus Biopharma Corporation
ABUS
|
425 K | $ 4.77 | 1.27 % | $ 792 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
481 K | $ 3.33 | 2.61 % | $ 257 M |  USA |
 |
AlloVir
ALVR
|
10.8 M | - | 4.14 % | $ 49.1 M | USA |
 |
Aptorum Group Limited
APM
|
433 K | $ 1.31 | 0.85 % | $ 7.14 M |  China |
 |
Ascendis Pharma A/S
ASND
|
14.2 M | $ 218.02 | -1.09 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
57.6 K | $ 3.2 | -2.74 % | $ 7.7 B |  Australia |
 |
BioVie
BIVI
|
74.5 K | $ 1.43 | -1.7 % | $ 2.11 M | USA |
 |
ARCA biopharma
ABIO
|
213 K | - | 1052.0 % | $ 415 M | USA |
 |
Acasti Pharma
ACST
|
75 K | - | 4.01 % | $ 150 M | Canada |
 |
BioNTech SE
BNTX
|
39.5 M | $ 94.46 | -0.37 % | $ 27.2 B | Germany |
 |
Adaptimmune Therapeutics plc
ADAP
|
5.38 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Aeglea BioTherapeutics
AGLE
|
625 K | - | - | $ 1.01 B | USA |
 |
Albireo Pharma
ALBO
|
3.08 M | - | -0.23 % | $ 916 M | USA |
 |
Alpine Immune Sciences
ALPN
|
756 K | - | - | $ 2.17 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
274 K | - | -11.43 % | $ 502 K | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
6.8 M | $ 25.93 | 2.61 % | $ 1.26 B | USA |
 |
Applied Molecular Transport
AMTI
|
4.64 M | - | - | $ 10.1 M | USA |
 |
Anika Therapeutics
ANIK
|
1.6 M | $ 9.58 | 0.21 % | $ 140 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
43 K | $ 0.28 | -1.82 % | $ 609 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
210 K | $ 14.27 | 1.28 % | $ 939 M | USA |
 |
Athersys
ATHX
|
1.01 M | - | 3.77 % | $ 22.4 M | USA |
 |
Acer Therapeutics
ACER
|
104 K | - | 2.71 % | $ 14 M | USA |
 |
AVROBIO
AVRO
|
878 K | - | 1083.1 % | $ 745 M | USA |
 |
Axon Enterprise
AXON
|
9.45 M | $ 563.27 | -0.18 % | $ 42.7 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
419 K | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
137 K | $ 2.33 | 1.3 % | $ 14.6 M | USA |
 |
AstraZeneca PLC
AZN
|
339 M | $ 90.67 | 0.94 % | $ 96.9 B | Britain |
 |
Acorda Therapeutics
ACOR
|
1.59 M | - | -24.86 % | $ 820 K | USA |
 |
Brickell Biotech
BBI
|
49 K | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
17.6 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
675 K | $ 11.68 | 1.26 % | $ 755 M | USA |
 |
Biogen
BIIB
|
86.4 M | $ 171.54 | -1.47 % | $ 25 B | USA |
 |
Abeona Therapeutics
ABEO
|
998 K | $ 5.34 | -0.37 % | $ 114 M | USA |
 |
ADiTx Therapeutics
ADTX
|
683 K | $ 2.11 | -5.61 % | $ 27.8 K | USA |
 |
Cellectar Biosciences
CLRB
|
59 K | $ 3.6 | -0.55 % | $ 44 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
11 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
3.29 M | - | -7.31 % | $ 87 M | USA |
 |
Advaxis
ADXS
|
166 K | - | -9.65 % | $ 45.9 M | USA |
 |
BioLineRx Ltd.
BLRX
|
522 K | $ 3.33 | 0.91 % | $ 908 M | Israel |